Clinical Trial Update: Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety and tolerability of the combination of Inotuzumab Ozogamicin (CMC-544) and rituximab in lymphoma, B-cell indications; study comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Lymphoma

Drugs mentioned

• Inotuzumab ozogamicin (inotuzumab ozogamicin)
• Rituximab (rituximab)

Snippet

Sponsor: Pfizer | Conditions: Lymphoma, B-Cell | Phase 1 | Status: COMPLETED | Results posted: 2019-03-15